{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=88",
    "query": {
      "intervention": "Control II",
      "page": 88
    },
    "page_size": 10
  },
  "pagination": {
    "page": 88,
    "page_size": 10,
    "total_count": 2670,
    "total_pages": 267,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=89&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=87&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T10:11:01.011Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01643590",
      "title": "Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Heart Failure"
      ],
      "interventions": [
        {
          "name": "JVS-100 15 mg dose Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "JVS-100 30 mg dose injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Juventas Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2012-07",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2014-02-07",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Gainesville, Florida • Tampa, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01643590"
    },
    {
      "nct_id": "NCT07882862",
      "title": "HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients With Persistent Hypogonadism After ADT for Treatment of Localized Prostate Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Clomiphene Citrate 25mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 83,
      "start_date": "2027-01-31",
      "completion_date": "2037-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07882862"
    },
    {
      "nct_id": "NCT00028288",
      "title": "Study of Daclizumab in Patients With Chronic, Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Facet Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2001-09",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-13",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 18,
      "location_summary": "Long Beach, California • Mission Viejo, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028288"
    },
    {
      "nct_id": "NCT01425970",
      "title": "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 210,
      "start_date": "2012-05",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • La Jolla, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01425970"
    },
    {
      "nct_id": "NCT00110708",
      "title": "Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism",
        "Autistic Disorder",
        "Child Development Disorders, Pervasive",
        "Gastrointestinal Diseases",
        "Signs and Symptoms, Digestive"
      ],
      "interventions": [
        {
          "name": "Oralgam (human immunoglobulin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PediaMed Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 120,
      "start_date": "2005-04",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2006-02-22",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110708"
    },
    {
      "nct_id": "NCT00646438",
      "title": "United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Strict Glycemic Control for one year post-op CABG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Heart & Vascular Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 120,
      "start_date": "2009-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2009-02-04",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646438"
    },
    {
      "nct_id": "NCT06067438",
      "title": "Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Esophageal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Amiodarone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2024-06-21",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06067438"
    },
    {
      "nct_id": "NCT02101385",
      "title": "Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasm of Breast",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Genomically Directed Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Observation/Standard Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bryan Schneider, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 193,
      "start_date": "2014-04-03",
      "completion_date": "2022-09-09",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02101385"
    },
    {
      "nct_id": "NCT03452540",
      "title": "Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Acute Decompensated Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "1000mg DS102 (BID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Afimmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-11-28",
      "completion_date": "2020-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Kansas City, Kansas • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452540"
    },
    {
      "nct_id": "NCT00796887",
      "title": "Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Extended-Release Niacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2009-04",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-03T10:11:01.011Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00796887"
    }
  ]
}